news & events
ysios portfolio archive
16.03.18
Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson’s disease
15.03.18
OxThera announces the randomization of the first patient into its phase III EPHEX study with Oxabact
09.03.18
AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury
06.03.18
Sanifit Announces Results of the Phase II Clinical Trial of SNF472 in Patients with Calciphylaxis
05.03.18
Kala Pharmaceuticals Appoints Gregory Perry to Board of Directors and as Audit Committee Chair
